All articles
Are GLP-1 Medications Safe for Depression and Anxiety?
Reading time:
5 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
Should I use GLP-1 Medications for my Depression/Anxiety?
So, what does this mean for people with depression and anxiety who are considering GLP-1 medications? It's important to remember that GLP-1 medications are not currently approved for the treatment of depression and anxiety, and their use for these conditions is still considered experimental. If you are interested in trying GLP-1 medications for mood or anxiety symptoms, you should discuss this with your healthcare provider and make sure that you understand the potential risks and benefits.
Your healthcare provider may recommend other treatments for depression and anxiety, such as therapy or medications that have been specifically approved for these conditions. If you do decide to try GLP-1 medications, your healthcare provider will monitor you closely for side effects and adjust your treatment as needed.
Conclusion
In conclusion, GLP-1 medications show promise as a potential treatment for depression and anxiety, but more research is needed to fully understand their safety and effectiveness for these conditions. If you are considering GLP-1 medications for mood or anxiety symptoms, it's important to discuss this with your healthcare provider and make an informed decision based on your individual circumstances. If you would like to learn more about GLP-1 medications or want to see if you might be eligible for medication-assisted weight loss, check out Mochi Health, where board-certified obesity medicine physicians can offer expertise in this realm!
References:
Pozzi M, Mazhar F, Peeters GGAM, Vantaggiato C, Nobile M, Clementi E, Radice S, Carnovale C. A systematic review of the antidepressant effects of glucagon-like peptide 1 (GLP-1) functional agonists: Further link between metabolism and psychopathology: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders. J Affect Disord. 2019 Oct 1;257:S0165-0327(19)30593-2. doi: 10.1016/j.jad.2019.05.044. Epub 2019 May 28. PMID: 31153593.
Kim YK, Kim OY, Song J. Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function. Front Pharmacol. 2020 Aug 14;11:1270. doi: 10.3389/fphar.2020.01270. PMID: 32922295; PMCID: PMC7456867.
Durell N, Franks R, Coon S, Cowart K, Carris NW. Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss. Journal of Pharmacy Technology. 2022;38(5):283-288. doi:10.1177/87551225221110850
Share this post
Weight loss
More articles















